These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26693810)

  • 1. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
    Skoglund K; Richter J; Olsson-Strömberg U; Bergquist J; Aluthgedara W; Ubhayasekera SJ; Vikingsson S; Svedberg A; Söderlund S; Sandstedt A; Johnsson A; Aagesen J; Alsenhed J; Hägg S; Peterson C; Lotfi K; Gréen H
    Ther Drug Monit; 2016 Apr; 38(2):230-8. PubMed ID: 26693810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity.
    Gréen H; Skoglund K; Rommel F; Mirghani RA; Lotfi K
    Eur J Clin Pharmacol; 2010 Apr; 66(4):383-6. PubMed ID: 20054526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring.
    Omran MM; Ibrahim AB; Abdelfattah R; Shouman SA; Hamza MS
    Eur J Clin Pharmacol; 2024 Jul; 80(7):1061-1068. PubMed ID: 38536418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
    Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
    J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
    Beumer JH; Natale JJ; Lagattuta TF; Raptis A; Egorin MJ
    Pharmacotherapy; 2006 Jul; 26(7):903-7. PubMed ID: 16803422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
    Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia.
    Capron A; Antunes MV; Wagner SC; Mattevi VS; Vieira N; Leite R; Reginato F; Capra M; Fogliatto L; Wallemacq P; Linden R
    Clin Chim Acta; 2016 Jan; 453():42-7. PubMed ID: 26657979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and pharmacokinetics of imatinib in pediatric patients.
    Suttorp M; Bornhäuser M; Metzler M; Millot F; Schleyer E
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):219-231. PubMed ID: 29076384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting.
    Eskazan AE
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1537-1538. PubMed ID: 27558360
    [No Abstract]   [Full Text] [Related]  

  • 11. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
    Bedewy AM; El-Maghraby SM
    Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
    Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Potential clinical benefit of therapeutic drug monitoring of imatinib in oncology].
    Turjap M; Juřica J; Demlová R
    Klin Onkol; 2015; 28(2):105-11. PubMed ID: 25882020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
    Teng JF; Mabasa VH; Ensom MH
    Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.
    Osorio S; Escudero-Vilaplana V; Gómez-Centurión I; González-Arias E; García-González X; Díez JL
    J Oncol Pharm Pract; 2019 Apr; 25(3):694-698. PubMed ID: 29199506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting.
    Faber E; Friedecký D; Mičová K; Rožmanová S; Divoká M; Jarošová M; Indrák K; Adam T
    Ann Hematol; 2012 Jun; 91(6):923-9. PubMed ID: 22231281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia.
    Wang Q; Jiang ZP; Zeng J; Zhu Y; Cai HL; Xiang DX; He Q; Shi XL; Zhong AN; Zhao XL; Xu P
    J Pharm Pharm Sci; 2020; 23(1):1-9. PubMed ID: 32027818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
    Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
    Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.